Company Overview

Company Overview

News & Events

  • Portola Announces Senior Management and Board Changes. PDF 50KB
  • Portola enters licensing agreement with Merck. PDF 32KB
  • Portola enters licensing agreement for Novel Antiplatelet Drug Elinogrel. PDF 28KB

Portola Pipeline

Portola Pipeline

Portola develops innovative therapeutics based on targets with established proofs of concept that are designed to provide significant advances over current treatments for cardiovascular disease and inflammation. The company has global development and commercialization agreements with two of the world’s leading pharmaceutical companies collectively valued at about $1 billion in upfront and milestone payments plus double-digit royalties on future sales.

Betrixaban, our oral direct Factor Xa inhibitor is licensed to Merck & Co., Inc., and elinogrel, our competitive and reversible P2Y12ADP receptor antagonist, is licensed to Novartis. Both betrixaban and elinogrel are Phase 2 product candidates that have best-in-class features to address the global multi-billion hospital, specialty, and chronic care anticoagulant and antiplatelet markets, respectively.

We also have proprietary pipeline programs that diversify our portfolio and could offer opportunities for accelerated development.

These include:

  • PRT061103, a thromboxane receptor antagonist, which is targeted to address a significant unmet need as a potential alternative for patients intolerant to aspirin;
  • A novel recombinant protein anticoagulant antidote, known as a Factor Xa inhibitor antidote, to help manage or reverse the bleeding complications in the tens of millions of patients expected to be treated with Factor Xa inhibitors or low-molecular weight heparin worldwide in the next decade; and
  • PRT062607, a novel, orally available, Syk-specific kinase inhibitor to treat chronic inflammatory diseases, including rheumatoid arthritis. This is a part of our broader program based on novel Syk and JAK inhibitors to treat additional inflammatory disease and oncology.

Our scientists are recognized leaders in the fields of platelet biology and thrombosis. Working together for more than a decade, our scientific team was the first to clone the platelet ADP receptor P2Y12, the target of both Plavix® and our own ADP receptor antagonist, elinogrel. Our team was also instrumental in the discovery, development and commercialization of the leading GP IIb-IIIa inhibitor, INTEGRILIN®.